NCT04534790 is a NA clinical trial of Low Dose Radiotherapy in COVID-19 Pneumonia, sponsored by Instituto Mexicano del Seguro Social.

Who is sponsoring NCT04534790?

NCT04534790 is sponsored by Instituto Mexicano del Seguro Social.

What drugs are being tested in NCT04534790?

Interventions in NCT04534790: Low Dose Radiotherapy.

What condition does NCT04534790 study?

NCT04534790 studies COVID-19 Pneumonia.

Is NCT04534790 still recruiting?

NCT04534790 is currently completed. Last updated 9 February 2021.

Last reviewed 2021-02-09 · How we verify

NCT04534790

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Anti-inflammatory Effect of Low-Dose Whole-Lung Radiation for COVID-19 Pneumonia

Completed NA Last updated 9 February 2021

What this trial tests

NA trial testing Low Dose Radiotherapy in COVID-19 Pneumonia in 30 participants. Completed in 8 January 2021.

Timeline

24 July 2020

Primary endpoint
12 December 2020

8 January 2021

Quick facts

Lead sponsor	Instituto Mexicano del Seguro Social
Phase	NA
Status	Completed
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	double
Primary purpose	treatment
Enrollment	30
Start date	24 July 2020
Primary completion	12 December 2020
Estimated completion	8 January 2021
Sites	1 location across Mexico

Drugs / interventions tested

Low Dose Radiotherapy

Conditions studied

COVID-19 Pneumonia — all drugs for COVID-19 Pneumonia →

Sponsor

Instituto Mexicano del Seguro Social — full company profile →

Who can join

Adults 18 to 100, any sex, with COVID-19 Pneumonia. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

There are several clinical studies that mention the benefits of treatment with low-dose radiation therapy to patients with COVID 19, so this study protocol will be started to determine if there is clinical improvement with treatment and low-dose radiation therapy. to all the lung.

Publications & conference data

8 peer-reviewed publications reference this trial (live from Europe PMC):

COVID-19 pneumonia treated with ultra-low doses of radiotherapy (ULTRA-COVID study): a single institution report of two cases.
Moreno-Olmedo E, Suárez-Gironzini V, Pérez M, Filigheddu T, et al · · 2021 · cited 19× · PMID 33502567 · DOI 10.1007/s00066-020-01743-4
The clinical efficacy of low-dose whole-lung irradiation in moderate-to-severe COVID-19 pneumonia: RTMX-20 trial.
Ortiz CS, Hernández D, Trujillo C, Calderón D, et al · · 2022 · cited 10× · PMID 34838890 · DOI 10.1016/j.radonc.2021.11.013
Low-Dose Whole Lung Irradiation for Treatment of COVID-19 Pneumonia: A Systematic Review and Meta-Analysis.
Kolahdouzan K, Chavoshi M, Bayani R, Darzikolaee NM. · · 2022 · cited 8× · PMID 35537577 · DOI 10.1016/j.ijrobp.2022.04.043
The Role of Ionizing Radiation for Diagnosis and Treatment against COVID-19: Evidence and Considerations.
Chalkia M, Arkoudis NA, Maragkoudakis E, Rallis S, et al · · 2022 · cited 7× · PMID 35159277 · DOI 10.3390/cells11030467
COVID-19: The Disease, the Immunological Challenges, the Treatment with Pharmaceuticals and Low-Dose Ionizing Radiation.
Yu J, Azzam EI, Jadhav AB, Wang Y. · · 2021 · cited 5× · PMID 34571861 · DOI 10.3390/cells10092212
COVID-19-Associated Pneumonia: Radiobiological Insights.
François S, Helissey C, Cavallero S, Drouet M, et al · · 2021 · cited 3× · PMID 34113249 · DOI 10.3389/fphar.2021.640040
Exploring the multifocal therapeutic approaches in COVID-19: A ray of hope.
Kumar A, Dey AD, Behl T, Chadha S, et al · · 2021 · cited 2× · PMID 33189613 · DOI 10.1016/j.intimp.2020.107156
Is Low-Dose Lung Radiotherapy for Severe COVID-19 Pneumonia a Therapeutic Alternative?
Safini F, Amaoui B, Oqbani K, Abbaoui S, et al · · 2024 · cited 1× · PMID 39165439 · DOI 10.7759/cureus.65033

Verify or expand the search:

Other trials of Low Dose Radiotherapy

Trials testing the same drug.

NCT06848465 — LDRT Combined With Immunochemotherapy for Colorectal Cancer With Liver Metastasis · Phase 1 · recruiting
NCT06349837 — Safety and Tolerability of LDRT Plus Concurrent Partial SBRT and Tislelizumab in Patients With Bulky Tumors · Phase 1 · recruiting
NCT05615142 — Safety and Tolerability of Low Dose Radiotherapy Concurrent SBRT and PD-1 Inhibitors in Advanced NSCLC. · Phase 1 · recruiting
NCT03812549 — Safety and Tolerability Evaluation of Sintilimab in Combination With Radiation in Stage IV NSCLC Patients · Phase 1 · completed
NCT03196778 — Low Dose Hemi-body Radiation For Recurrent Prostate Cancer · NA · completed

Other recruiting trials for COVID-19 Pneumonia

Currently open trials in the same condition.

NCT06601998 — Cardiovascular Disease Progression in Survivors of Community Acquired Pneumonia and Lung Infection by Covid-19. · recruiting
NCT06501599 — AI-based System for Assessing Suspected Viral Pneumonia Related Lung Changes · recruiting
NCT06402318 — Passive Detection- SARS-CoV-2 (COVID-19) A&M Breathalyzer (PROTECT Kiosk) for Operational Medicine · recruiting
NCT05765396 — SARS-CoV-2/COVID-19 Study of Next Generation Non-Invasive Passive Detection Technologies · active not recruiting
NCT06927622 — Corona Virus Disease 2019 Cohort Study · recruiting

Other Instituto Mexicano del Seguro Social trials

Trials by the same sponsor.

NCT07536009 — "Effectiveness of a Telerehabilitation Program Versus a Conventional Rehabilitation Program in Patients With Subacromial · NA · not yet recruiting
NCT06632184 — Peritoneal Lavage Using Saline or Saline With Ondansetron for Pain Control After Laparoscopic Cholecystectomy · Phase 4 · active not recruiting
NCT07073846 — Effect of Lidocaine-Dexmedetomidine on Pain, Inflammation, and Oxidative Stress After Bariatric Surgery. · Phase 4 · recruiting
NCT07406971 — Safety of Transmucosal Capsaicin Sphenopalatine Ganglion Stimulation in Acute Ischemic Stroke · Phase 2 · recruiting
NCT07134504 — Primary Prostatic Lymphoma on a 66 Year-old Male in Mexico. · completed

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT04534790 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 9 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Instituto Mexicano del Seguro Social
Last refreshed: 9 February 2021

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04534790.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing